Menu
Not yet recruiting NCT04750252

Safety and Tolerability of StroMel™ in Subjects with Moderate to Severe Osteoarthritis of the Knee Joint

Phase I / Phase II Interventional Osteo Arthritis Knee

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: StroMel.
Who it may be relevant to
Registry conditions: Osteo Arthritis Knee. Basic parameters: 25 years — 65 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

An Open Label Study to Evaluate Safety and Tolerability of StroMel™ in Subjects with Moderate to Severe Osteoarthritis of the Knee Joint

Overview

The aim of this trial is to evaluate the safety and tolerability of autologous StroMel™ for the treatment of moderate to severe OA of the knee joint.

Interventions

  • Biological StroMel
    Autologous MSC

Primary outcome measures

  • Safety of StroMel in subjects with moderate to severe OA of the kneee [Time frame: 12 months]
  • Overall Safety of StroMel [Time frame: 12 months]
Secondary outcome measures (2)
  • Efficacy of StroMel in managing OA of the knee [Time frame: 52 weeks]
  • Efficacy of StroMel in assessment of OA of the knee post-treatment [Time frame: 52 weeks]

Eligibility criteria

Inclusion criteria

  • Adults between the ages of 25-65 years
  • Body Mass Index (BMI) less than 40 kg/m2
  • Ambulatory and in good general health as described by vital signs (blood pressure 90/60 mm Hg to 120/80 mm Hg, pulse rate 60-100 beats per minute, temperature 97.2-99.1 °F) and normal blood chemistry.
  • Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain score of ≥ 11 (worst possible = 20) over the previous 7 days
  • OA of the knee with Kellgren and Lawrence radiographic classification (Grade 2-4 inclusive) within the last 6 months
  • Minimum score of 40 out of possible 100 on the VAS (Visual Analog Scale) for pain.
  • Patients who have failed to adequately respond for at least 6 months to at least 2 OA therapies that include conservative, non-pharmacological therapy and simple analgesics (e.g., acetaminophen); nonsteroidal anti-inflammatory drugs (NSAIDS); avoidance of activities that cause joint pain; exercise; weight loss; physical therapy; and removal of excess fluid from the knee.
  • Have suitable knee joint anatomy for intra-articular injection.
  • For adults of reproductive potential: use of effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation.

Exclusion criteria

  • Reactive arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or arthritis associated with inflammatory bowel disease.
  • Subject with an infection that requires parenteral antibiotic administration.
  • Active infection or crystal disease in the index joint within 1 month of screening
  • History of fracture in the index limb, joint instability, or history of acute dislocation within 12 months of screening, or fracture with sequelae at any time
  • Intra-articular treatment of any joint with any of the following agents within 6 months of screening: Any corticosteroid preparation (investigational or marketed), sodium hyaluronate, any biologic agent (e.g., platelet rich plasma (PRP) injection, stem cells, prolotherapy, amniotic fluid injection); investigational six months prior to enrollment.
  • Presence of surgical hardware or other foreign body in the index joint
  • Subjects who were administered with immunosuppressants such as cyclosporin A or azathioprine within 6 weeks before screening.
  • Planned or anticipated surgery of the joint during the study period
  • Allergies to anesthesia
  • Subjects who tested positive for HIV, HCV, WNV, CMV, HBV, HTLV, ZIKA, syphilis, flu or COVID-19. Note: CMV is not a relevant communicable disease agent. A subject who tests positive or reactive for CMV is not necessarily ineligible. Physicians will determine donor eligibility for subjects with positive CMV test results.
  • History of lipid disorders: lipedema, lipomatosis, or lipodystrophies.
  • Active cancer, chemotherapy, or other malignancies in the last 6 months.
  • Recent history of DVT or pulmonary embolism requiring anticoagulants or other medicines per the hematologist.
  • Subject who participated in another clinical trial within 3 months before the screening visit
  • Any illness which, in the Investigator's judgment, will interfere with the subject's ability to comply with the protocol, compromise patient safety, or interfere with the interpretation of the study results.
  • Subjects who are breastfeeding
  • Subjects with uncontrolled arrhythmias
  • Subjects with hemophilia; factor II, V, VII, X, or XII deficiencies; or Von Willebrand's disease.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

United States · 1 center
  • Mukesh — Gaithersburg

Identifiers

NCT: NCT04750252 · StroMel-01

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗